Skip to main content
Bundle Skin Health Bundle

Bundle

Skin Health Bundle

A focused digital collection for skin changes, symptom and photo tracking, infection warnings, triggers, routines, sensory concerns, and provider preparation.

Format digital
Access $79.00
Item ID bndl044
Get Access Add to Cart Back to Library

Educational support only. This resource complements, not replaces, provider instructions, facility policy, or medical advice.

Item Details

About this resource

Start here

The essentials before you go deeper.

Skin Health Bundle

This digital bundle connects the Skin Health and Allergy Management Companions with selected skin-change, photo-log, infection-warning, trigger, routine, sensory-management, and self-management tools. Components were selected for practical overlap between skin symptoms, exposure patterns, and daily participation.

The collection supports observation and communication and complements--not replaces--clinical assessment.

skin health bundle skin symptom tracker provider photo log wound red flags skin trigger tracker skin care planner itch sensory management CarePlanCompass

Bundle Contents

Included in this bundle

This bundle includes the following companions, guidance resources, and workbook tools from the bundle matrix.

acd044 Skin Health Companion
acd045 Allergy Management Companion
dcm001 Condition Overview & What to Expect
dcm025 Skin Symptom & Change Tracker
dcm027 Provider Visit & Photo Log
dcm026 Infection & Wound Red Flags
dcm005 Flare-Up Action Plan
hmb015 Skin-Care Routine Planner
hmb016 Skin Trigger Tracker
mwp019 Itch & Sensory Management
kpd002 Daily Health Journal
kpd005 Healthy Habits Journal
kpd007 Emotional Regulation Workbook

Next Step Hub

Your next best move starts here.

Choose the matched bundle, continue with this resource, review connected tools, or check the evidence behind the guidance.

This resource

Continue with this item

Use this path when this resource is the book, guide, or support tool you came for.

Get Access

Clinical Confidence

Evidence behind this resource

50 sources
Evidence-informed

Guidance is connected to the CarePlanCompass™ reference database.

AMA-style references

Sources are formatted for clinical review and transparency.

Methodology available

Users can review how references support the resource framework.

View Clinical Evidence & Methodology

View clinical references 50 sources
  1. Chu AWL, Wen A, Guyatt GH, Rao M, Bakaa L, Zhao IX et al. Antihistamines for atopic dermatitis (eczema): systematic review and network meta-analysis of randomised trials. BMJ (Clinical research ed.). 2026;394:e100163. doi:10.1136/bmj-2026-100163 Source
  2. Santos AF, Riggioni C, Agache I, Akdis CA, Akdis M, Alvarez-Perea A et al. EAACI guidelines on the management of IgE-mediated food allergy. Allergy. 2025;80(1):14-36. doi:10.1111/all.16345 Source
  3. Kessels RPC. Patients' memory for medical information. J R Soc Med. 2003;96(5):219-222. doi:10.1258/jrsm.96.5.219
  4. Byrne A, Macdonald DB, Kirkpatrick IDC, Pham M, Green CR, Copaescu AM et al. CAR/CSACI Practice Guidance for Contrast Media Hypersensitivity. Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes. 2025;76(3):400-416. doi:10.1177/08465371241311253 Source
  5. Singleton H, Hodder A, Almilaji O, Ersser SJ, Heaslip V, O'Meara S et al. Educational and psychological interventions for managing atopic dermatitis (eczema). The Cochrane database of systematic reviews. 2024;8(8):CD014932. doi:10.1002/14651858.CD014932.pub2 Source
  6. Agency for Healthcare Research and Quality. Be more engaged in your healthcare. AHRQ;Updated November 2024. Accessed October 15, 2026. https://www.ahrq.gov/questions/be-engaged/index.html Source
  7. Golden DBK, Wang J, Waserman S, Akin C, Campbell RL, Ellis AK et al. Anaphylaxis: A 2023 practice parameter update. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2024;132(2):124-176. doi:10.1016/j.anai.2023.09.015 Source
  8. Chu AWL, Wong MM, Rayner DG, Guyatt GH, Díaz Martinez JP, Ceccacci R et al. Systemic treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. 2023;152(6):1470-1492. doi:10.1016/j.jaci.2023.08.029 Source
  9. Elwyn G, Frosch D, Thomson R, et al. Shared decision making: a model for clinical practice. J Gen Intern Med. 2012;27(10):1361-1367. doi:10.1007/s11606-012-2077-6
  10. Yepes-Nuñez JJ, Guyatt GH, Gómez-Escobar LG, Pérez-Herrera LC, Chu AWL, Ceccaci R et al. Allergen immunotherapy for atopic dermatitis: Systematic review and meta-analysis of benefits and harms. The Journal of allergy and clinical immunology. 2023;151(1):147-158. doi:10.1016/j.jaci.2022.09.020 Source
  11. Muraro A, Worm M, Alviani C, Cardona V, DunnGalvin A, Garvey LH et al. EAACI guidelines: Anaphylaxis (2021 update). Allergy. 2022;77(2):357-377. doi:10.1111/all.15032 Source
  12. American Occupational Therapy Association. Occupations and everyday activities. AOTA;Accessed October 15, 2026. https://www.aota.org/practice/domain-and-process/occupations-everyday-activities Source
  13. Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nuñez JJ, Gomez-Escobar L et al. Topical treatments for atopic dermatitis (eczema): Systematic review and network meta-analysis of randomized trials. The Journal of allergy and clinical immunology. 2023;152(6):1493-1519. doi:10.1016/j.jaci.2023.08.030 Source
  14. de Silva D, Singh C, Muraro A, Worm M, Alviani C, Cardona V et al. Diagnosing, managing and preventing anaphylaxis: Systematic review. Allergy. 2021;76(5):1493-1506. doi:10.1111/all.14580 Source
  15. American Occupational Therapy Association. Occupational Therapy Practice Framework: Domain and Process—Fourth Edition. Am J Occup Ther. 2020;74(Suppl 2):7412410010p1-7412410010p87. doi:10.5014/ajot.2020.74S2001 Source
  16. Riggioni C, Oton T, Carmona L, Du Toit G, Skypala I, Santos AF. Immunotherapy and biologics in the management of IgE-mediated food allergy: Systematic review and meta-analyses of efficacy and safety. Allergy. 2024;79(8):2097-2127. doi:10.1111/all.16129 Source
  17. Drucker AM, Morra DE, Prieto-Merino D, Ellis AG, Yiu ZZN, Rochwerg B et al. Systemic Immunomodulatory Treatments for Atopic Dermatitis: Update of a Living Systematic Review and Network Meta-analysis. JAMA dermatology. 2022;158(5):523-532. doi:10.1001/jamadermatol.2022.0455 Source
  18. Kinnersley P, Edwards A, Hood K, et al. Interventions before consultations for helping patients address their information needs. Cochrane Database Syst Rev. 2007;(3):CD004565. doi:10.1002/14651858.CD004565.pub2
  19. Zuberbier T, Wood RA, Bindslev-Jensen C, Fiocchi A, Chinthrajah RS, Worm M et al. Omalizumab in IgE-Mediated Food Allergy: A Systematic Review and Meta-Analysis. The journal of allergy and clinical immunology. In practice. 2023;11(4):1134-1146. doi:10.1016/j.jaip.2022.11.036 Source
  20. Oykhman P, Dookie J, Al-Rammahy H, de Benedetto A, Asiniwasis RN, LeBovidge J et al. Dietary Elimination for the Treatment of Atopic Dermatitis: A Systematic Review and Meta-Analysis. The journal of allergy and clinical immunology. In practice. 2022;10(10):2657-2666.e8. doi:10.1016/j.jaip.2022.06.044 Source
  21. Agency for Healthcare Research and Quality. Use the teach-back method: tool 5. Health Literacy Universal Precautions Toolkit. 3rd ed;Updated April 2024. Accessed October 15, 2026. https://www.ahrq.gov/health-literacy/improve/precautions/tool5.html Source
  22. Roongpisuthipong W, Klangjareonchai T, Kurathong S, Roongpisuthipong A. Efficacy and safety of cannabidiol oil in psoriasis: a randomized, double-blind, placebo-controlled trial. The Journal of dermatological treatment. 2026;37(1):2604448. doi:10.1080/09546634.2025.2604448 Source
  23. Halken S, Muraro A, de Silva D, Khaleva E, Angier E, Arasi S et al. EAACI guideline: Preventing the development of food allergy in infants and young children (2020 update). Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2021;32(5):843-858. doi:10.1111/pai.13496 Source
  24. National Library of Medicine. Understanding medical words tutorial. MedlinePlus;Updated September 30, 2024. Accessed October 15, 2026. https://medlineplus.gov/medicalwords.html Source
  25. Wang S, Li F. Comparison of patient-reported outcomes in patients achieving complete versus near-complete skin clearance following Vunakizumab treatment: a post-hoc analysis of a phase III trial. Naunyn-Schmiedeberg's archives of pharmacology. 2026;399(2):2417-2425. doi:10.1007/s00210-025-04490-4 Source
  26. Pouessel G, Dölle-Bierke S, Karaca-Altintas Y, Lange L, Breiding M, Köhli A et al. Food-induced anaphylaxis in educational settings: Data from the European anaphylaxis registry. Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology. 2026;37(6):e70404. doi:10.1111/pai.70404 Source
  27. Lorig KR, Holman HR. Self-management education: history, definition, outcomes, and mechanisms. Ann Behav Med. 2003;26(1):1-7. doi:10.1207/S15324796ABM2601_01
  28. Heidari Z, Gharibi G, Alaeen H, Ghadrdan E, Shahrestanaki E, Sadeghi-Ghadi Z et al. Melatonin Supplementation in Adult Patients With Atopic Dermatitis: A Randomized Clinical Trial. Journal of pineal research. 2026;78(2):e70130. doi:10.1111/jpi.70130 Source
  29. Matricardi PM, van Hage M, Custovic A, Korosec P, Santos AF, Valenta R. Molecular allergy diagnosis enabling personalized medicine. The Journal of allergy and clinical immunology. 2025;156(3):485-502. doi:10.1016/j.jaci.2025.01.014 Source
  30. Talevski J, Wong Shee A, Rasmussen B, et al. Teach-back: a systematic review of implementation and impacts. PLoS One. 2020;15(4):e0231350. doi:10.1371/journal.pone.0231350
  31. Sousa-Pinto B, Bousquet J, Vieira RJ, Schünemann HJ, Zuberbier T, Bognanni A et al. Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part I-Guidelines on Intranasal Treatments. Allergy. 2026;81(4):954-976. doi:10.1111/all.70131 Source
  32. Yosipovitch G, Lio PA, Rosmarin D, Legat FJ, Serra-Baldrich E, Carrascosa JM et al. Lebrikizumab Improved Itch Symptoms and Reduced Itch Interference on Sleep over 52 Weeks in Patients with Moderate-to-Severe Atopic Dermatitis in Two Phase 3 Trials. Dermatology (Basel, Switzerland). 2025;241(4):325-335. doi:10.1159/000547142 Source
  33. Vieira RJ, Sousa-Pinto B, Bousquet J, Schünemann HJ, Zuberbier T, Bognanni A et al. Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI Guidelines-2024-2025 Revision: Part II-Guidelines on Oral and Ocular Treatments. Allergy. 2026;81(6):1947-1970. doi:10.1111/all.70305 Source
  34. Ständer S, Yosipovitch G, Simpson EL, Kim BS, Kabashima K, Thaçi D et al. Onset and Long-Term Maintenance of Optimal Itch Response in Adult Patients with Moderate-to-Severe Atopic Dermatitis Treated with Dupilumab: Post Hoc Analysis from Two Phase 3 Trials. Advances in therapy. 2025;42(4):1800-1810. doi:10.1007/s12325-025-03124-8 Source
  35. Zhu C, Feng B, Pan J, Ma J, Hu B, Liu L. Early itch relief with ivarmacitinib improves quality of life, working productivity, and sleep quality in patients with moderate-to-severe atopic dermatitis: a post hoc analysis of a phase III trial. The Journal of dermatological treatment. 2025;36(1):2558995. doi:10.1080/09546634.2025.2558995 Source
  36. Licari A, Magri P, De Silvestri A, Giannetti A, Indolfi C, Mori F et al. Epidemiology of Allergic Rhinitis in Children: A Systematic Review and Meta-Analysis. The journal of allergy and clinical immunology. In practice. 2023;11(8):2547-2556. doi:10.1016/j.jaip.2023.05.016 Source
  37. Li Y, Yang J, Liu R, Xiang Y, Zhang Y, Zheng M et al. Multi-omics elucidation of HDRSD alleviating allergic rhinitis via IL-1β/TRPV1 pathway regulation. Journal of ethnopharmacology. 2026;357:120936. doi:10.1016/j.jep.2025.120936 Source
  38. Silverberg JI, Wollenberg A, Reich A, Thaçi D, Legat FJ, Papp KA et al. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials. Lancet (London, England). 2024;404(10451):445-460. doi:10.1016/S0140-6736(24)01203-0 Source
  39. Bousquet J, Sousa-Pinto B, Vieira RJ, Schünemann HJ, Zuberbier T, Bognanni A et al. Methodology for the Development of the Allergic Rhinitis and Its Impact on Asthma (ARIA)-EAACI 2024-2025 Guidelines: From Evidence-to-Decision Frameworks to Digitalised Shared Decision-Making Algorithms. Allergy. 2026;81(2):427-453. doi:10.1111/all.70100 Source
  40. Silverberg JI, Bunick CG, Hong HC, Mendes-Bastos P, Stein Gold L, Costanzo A et al. Efficacy and safety of upadacitinib versus dupilumab in adults and adolescents with moderate-to-severe atopic dermatitis: week 16 results of an open-label randomized efficacy assessor-blinded head-to-head phase IIIb/IV study (Level Up). The British journal of dermatology. 2024;192(1):36-45. doi:10.1093/bjd/ljae404 Source
  41. McMurray JC, Bingemann TA, Golden DBK. Venom Anaphylaxis. Immunology and allergy clinics of North America. 2026;46(2):325-345. doi:10.1016/j.iac.2026.01.006 Source
  42. Kurt T, Vossen D, Schumacher F, Strunk J, Fedkov D, Peine C et al. Effect of Lifestyle Counselling via a Mobile Application on Disease Activity Control in Inflammatory Arthritis: A Single-Blinded, Randomized Controlled Study. Nutrients. 2024;16(10). doi:10.3390/nu16101488 Source
  43. Ma M, Duncan D, Bartoszko J. Perioperative anaphylaxis: an update on pathophysiology, diagnosis, and management. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 2025;72(4):649-674. doi:10.1007/s12630-025-02915-5 Source
  44. Silverberg JI, Gooderham MJ, Paller AS, Deleuran M, Bunick CG, Gold LFS et al. Early and Sustained Improvements in Symptoms and Quality of Life with Upadacitinib in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: 52-Week Results from Two Phase III Randomized Clinical Trials (Measure Up 1 and Measure Up 2). American journal of clinical dermatology. 2024;25(3):485-496. doi:10.1007/s40257-024-00853-4 Source
  45. Dribin TE, Muraro A, Camargo CA, Turner PJ, Wang J, Roberts G et al. Anaphylaxis definition, overview, and clinical support tool: 2024 consensus report-a GA2LEN project. The Journal of allergy and clinical immunology. 2025;156(2):406-417.e6. doi:10.1016/j.jaci.2025.01.021 Source
  46. Asilian A, Mohammadian P, Hosseini SM, Heidaripour F, Yekta A, Nateghi MR. Comparison of the effect of topical triamcinolone 0.1% cream with sulfur 2.0% cream in the treatment of patients with hand eczema: A randomized controlled trial. Journal of cosmetic dermatology. 2024;23(5):1753-1757. doi:10.1111/jocd.16208 Source
  47. Luccioli S, Seabol L. Anaphylaxis in children: Latest insights. Allergy and asthma proceedings. 2025;46(3):168-184. doi:10.2500/aap.2025.46.250005 Source
  48. Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A et al. Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis. The New England journal of medicine. 2023;388(12):1080-1091. doi:10.1056/NEJMoa2206714 Source
  49. Almaci M, Treudler R, Breiding M, Köhli A, Lange L, Pföhler C et al. Allergen immunotherapy-induced anaphylaxis: Data from the European Anaphylaxis Registry. Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology. 2025;134(6):724-730. doi:10.1016/j.anai.2025.02.012 Source
  50. Kwatra SG, Yosipovitch G, Legat FJ, Reich A, Paul C, Simon D et al. Phase 3 Trial of Nemolizumab in Patients with Prurigo Nodularis. The New England journal of medicine. 2023;389(17):1579-1589. doi:10.1056/NEJMoa2301333 Source

CarePlanCompass™"

Clarity that travels with you.

CarePlanCompass™ resources are designed to complement provider instructions, improve follow-through, and help people ask better questions at the right time.

Browse Library Ask a Question